Nothing Special   »   [go: up one dir, main page]

Plotnik, 2018 - Google Patents

The Role of CS1 Fibronectin in HIV-1 Infection of α4β7+ T Lymphocytes

Plotnik, 2018

View PDF
Document ID
7725678317677802757
Author
Plotnik D
Publication year

External Links

Snippet

A hallmark of Human Immunodeficiency Virus type 1 (HIV-1) pathogenesis is the profound depletion of CD4+ T lymphocytes within gut-associated lymphoid tissues (GALT), and persistent immune dysfunction at mucosal sites. It has been demonstrated that gut-homing …
Continue reading at digital.lib.washington.edu (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—AIDS or HTLV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse Transcribing RNA Viruses
    • C12N2740/00011—Reverse Transcribing RNA Viruses
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Similar Documents

Publication Publication Date Title
US9896509B2 (en) Use of antagonists of the interaction between HIV GP120 and α4β7 integrin
Moog et al. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals
CA2224003C (en) Fluorescence resonance energy transfer screening assay for the identification of hiv-1 envelope glycoprotein-medicated cell
Morozov et al. Single mutations in the transmembrane envelope protein abrogate the immunosuppressive property of HIV-1
EP3497133A1 (en) Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients
Ensoli et al. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4+ T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial
McKEATING et al. Monoclonal antibodies to the C4 region of human immunodeficiency virus type 1 gp120: use in topological analysis of a CD4 binding site
Humbert et al. Mimotopes selected with antibodies from HIV‐1‐neutralizing long‐term non‐progressor plasma
Dreyer et al. Primary isolate neutralization by HIV type 1-infected patient sera in the era of highly active antiretroviral therapy
Zhang et al. The bis-azo compound FP-21399 inhibits HIV-1 replication by preventing viral entry
Jacotot et al. HIV-1 envelope glycoproteins-mediated apoptosis is regulated by CD4 dependent and independent mechanisms
Plotnik The Role of CS1 Fibronectin in HIV-1 Infection of α4β7+ T Lymphocytes
Soper et al. Various plus unique: viral protein U as a plurifunctional protein for HIV-1 replication
Plotnik et al. Extracellular matrix proteins mediate HIV-1 gp120 interactions with α4β7
Holl et al. Stimulation of HIV-1 replication in immature dendritic cells in contact with primary CD4 T or B lymphocytes
JP2017529355A (en) Treatment and functional healing of HIV infection with monoclonal antibodies against CD4 that mediate competitive HIV entry inhibition
Jinno-Oue et al. The synthetic peptide derived from the NH2-terminal extracellular region of an orphan G protein-coupled receptor, GPR1, preferentially inhibits infection of X4 HIV-1
Miyagi et al. Antibody-mediated enhancement of HIV-1 and HIV-2 production from BST-2/tetherin-positive cells
TW202402788A (en) Methods of identifying hiv patients sensitive to therapy with gp120 cd4 binding site-directed antibodies
Burrer et al. Polyclonal immunoglobulin G from patients neutralizes human immunodeficiency virus type 1 primary isolates by binding free virions, but without interfering with an initial CD4-independent attachment of the virus to primary blood mononuclear cells
Featherstone The Antiviral Mechanism of SERINC5 on HIV-1 Infection
Anderson-Daniels Molecular Mechanisms Of HIV-1 Maturation And Host Factor Utilization
Mugisha Molecular Characterization of Integrase-RNA Interactions and Their Role in the Replication of HIV-1 and Other Retroviruses
Yolitz Variations in protein processing lead to variations in structure and function of the HIV-1 envelope protein
Gong Do Mucosal Immunoglobulin M Antibodies Prevent Mucosal Simian-Human Immunodeficiency Virus Transmission?